1747-P: Hospitalizations and Outcomes in Adults with Type 2 Diabetes (T2D) Treated with Weekly Insulin Efsitora Alfa (Efsitora): Results from the QWINT Program

Introduction and Objective: QWINT 1-4 were phase 3 trials assessing the efficacy and safety of efsitora, an innovative once-weekly basal insulin for treatment of T2D, compared to daily basal insulin. This post hoc analysis examined hospitalizations and outcomes of QWINT participants. Methods: Adults with T2D (QWINT-1-4; efsitora N=1883, comparator N=1556) were randomized to efsitora or comparators (degludec or glargine). Participants with hospitalizations for any reason were analyzed for incidence, length of stay (LOS), trial completion, and hypoglycemia rates. Results: The hospitalization incidence and LOS were similar between groups (9.2% n: 173 vs. 7.1% n: 110 and a median of 5.0 days vs. 5.0 days) in efsitora vs. comparators. Most participants with hospitalizations completed the trial treatment (73.4% vs. 83.6%). Clinically significant hypoglycemia reported before and after hospitalization was similar between the pooled efsitora and comparator groups (Figure). Data for hypoglycemia during hospitalization is not included due to differences in reporting methods and limited availability. Conclusion: Participants treated with efsitora had similar incidence of hospitalizations, with limited impact on hypoglycemia rates or trial discontinuation compared to daily basal comparators. Disclosure A. Philis-Tsimikas: Research Support; Current; Dexcom, Inc., Lilly, Novo Nordisk. Advisory Panel; Current; Novo Nordisk, Gan Current; Sanofi-Aventis U.S. R.J. Galindo: Consultant; Ended; Abbott, Boehringer Ingelheim International GmbH, Dexcom, Inc., Eli Lilly and Company, Gan Current; Roche Pharmaceuticals, Boehringer Ingelheim International GmbH, Novo Nordisk. B. Guerci: Other - member of the EASD; Current; European Association for the Study of Diabetes. Consultant; Current; Eli Lilly and Company. Advisory Panel; Current; Novo Nordisk. Board Member; Current; Dexcom, Inc. Advisory Panel; Current; Medtronic. Research Support; Current; Insulet Corporation. Consultant; Current; AstraZeneca. Board Member; Current; Ypsomed AG, Pfizer Inc. Consultant; Current; Abbott. Advisory Panel; Current; Sanofi. D. Kruger: Advisory Panel; Current; Abbott Diabetes. Speaker's Bureau; Current; Abbott. Advisory Panel; Current; Dexcom, Inc. Speaker's Bureau; Current; Dexcom, Inc. Research Support; Current; Abbott Diabetes. Advisory Panel; Current; Eli Lilly and Company. Speaker's Bureau; Current; Eli Lilly and Company. Advisory Panel; Current; Novo Nordisk. Speaker's Bureau; Current; Novo Nordisk. Research Support; Current; Insulet Corporation. Advisory Panel; Current; MannKind Corporation, Medtronic, Provention Bio, Inc., CeQur SA, Corcept Therapeutics. Speaker's Bureau; Current; CeQur SA, Corcept Therapeutics. Research Support; Current; Abbott Diabetes. Speaker's Bureau; Current; Sanofi. Advisory Panel; Current; Tandem Diabetes Care, Inc. Speaker's Bureau; Current; Tandem Diabetes Care, Inc. Research Support; Current; Tandem Diabetes Care, Inc. Advisory Panel; Current; Insulet Corporation. Speaker's Bureau; Current; Insulet Corporation. Consultant; Current; Sequel. Speaker's Bureau; Current; sequel. Research Support; Current; sequel. R. Threlkeld: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. B. Mushala: None. E.M. Levasseur: None. S. Cp: None. A. Goldyn: None.